{
  "docId": "019de070-fbaf-759b-8cbd-9f18172b1352",
  "docSlug": "7d8ead18d80cb869cda17e33a74aeb0b",
  "documentTitle": "BioNTech | Results Presentation Deck | 30 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 30,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fbaf-759b-8cbd-9f18172b1352/7",
  "deckHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352",
  "deckJsonHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352.json",
  "deckAnchorHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "*as of May 6. In March 2021, BioNTech announced its Full Year 2020 Financial Results and Corporate Update as a part of the Annual Report filed in Form 20-F...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9c4e399-46e9-42a4-b901-f324f8c5e6e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.225
      },
      "kind": "list",
      "text": "First Patients Dosed in Multiple First-in-Human Studies: Next generation CAR-T in combination with CARVac (BNT211), NEO-STIM Neoantigen-targeting T cell therapy (BNT221), Ribocytokine (BNT151)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29f98f44-bbd3-450d-ae77-08c443566795",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.92,
        "x": 0.04,
        "y": 0.515
      },
      "kind": "list",
      "text": "Executional Excellence in Infectious Disease with COVID-19 Vaccine: >450M doses shipped, ~1.8 billion doses contracted, €2.0 billion revenues, topline efficacy results, 100% efficacy in adolescents",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc2e152e-ad9b-497d-b909-e13b1b0e96f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Highlights From First Quarter 2021 and Beyond",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a305f4c-160e-4922-8999-25c9e9f4c123",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "15479899-563a-454d-9308-df3dd803567b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The deck highlights the company's transformation and focus on COVID-19 vaccine reach",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "acfebc91-ffe5-4ab0-8668-9619a540ee49",
      "evidence": "The deck explains the company's approach to immunotherapy and its potential",
      "position": 0,
      "objective": "Why BioNTech's immunotherapy approach is effective",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}